-$0.50 EPS Expected for Invuity, Inc. (IVTY) This Quarter
Equities research analysts forecast that Invuity, Inc. (NASDAQ:IVTY) will report earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Invuity’s earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.54). Invuity posted earnings of ($0.56) per share during the same quarter last year, which would suggest a positive year over year growth rate of 10.7%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 13th.
According to Zacks, analysts expect that Invuity will report full-year earnings of ($2.41) per share for the current year, with EPS estimates ranging from ($2.51) to ($2.32). For the next financial year, analysts anticipate that the company will post earnings of ($1.92) per share, with EPS estimates ranging from ($2.23) to ($1.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Invuity.
Invuity (NASDAQ:IVTY) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.04. The firm had revenue of $9.60 million during the quarter, compared to analyst estimates of $9.87 million. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%.
Invuity (IVTY) opened at $5.60 on Monday. The firm has a market capitalization of $95.98, a PE ratio of -2.27 and a beta of -0.25. The company has a current ratio of 2.90, a quick ratio of 2.47 and a debt-to-equity ratio of 5.39. Invuity has a 12-month low of $5.40 and a 12-month high of $9.70.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVTY. Citadel Advisors LLC purchased a new position in Invuity in the second quarter worth about $101,000. OxFORD Asset Management LLP purchased a new position in Invuity in the second quarter worth about $374,000. CAPROCK Group Inc. grew its position in Invuity by 28.6% in the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 10,000 shares in the last quarter. Royce & Associates LP grew its position in Invuity by 141.9% in the second quarter. Royce & Associates LP now owns 98,939 shares of the medical instruments supplier’s stock worth $717,000 after acquiring an additional 58,033 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC purchased a new position in Invuity in the second quarter worth about $1,549,000. Institutional investors own 69.06% of the company’s stock.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.